The effect of carnosine supplementation in type 2 diabetic patients

The effect of carnosine supplementation on advanced glycation endproductsandtheir soluble reseptor, metabolic condition and oxidative indices in type2 diabetic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016011211689N2

Enrollment

Registered

2016-02-01

Start date

2016-02-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Carnosine capsule (500 mg, twice daily, totall dose of 1000 mg, for 3 month). Intervention 2: placebo capsule (micro crystalline cellulose ).

Placebo

Carnosine capsule (500 mg, twice daily, totall dose of 1000 mg, for 3 month)

placebo capsule (micro crystalline cellulose )

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusuion criteria: : 1- Patients with type 2 diabetes age:30-60 2- patients using oral agents 3-BMI40 2- inflammatory and alergic disease 3-menopause 4- use of multivitamine-mineral 3 month prior to the study 4- use of corton or anti inflammetory steroid drugs 4- change in dosage of bloos sugar lowering drugs 5- chang in physical activity (duration and intensity) 6-use of insulin 7- patients affected with Poly cystic ovary syndrome 8- cardiovascular, kidney, liver disaese (exept fatty liver),9-hypo and hypertyroidism 9- Pregnency and lactation

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Srume pentosidine. Timepoint: prior to the study and 3 month after. Method of measurement: ElISA.;Carboxymethyllysine. Timepoint: prior to the study and 3 month after. Method of measurement: ElISA.;SRAGE. Timepoint: prior to the study and 3 month after. Method of measurement: ElISA.;TG-Total cholestrol-LDL- HDL. Timepoint: prior to the study and 3 month after. Method of measurement: ElISA.;Fasting blood suger. Timepoint: prior to the study and 3 month after. Method of measurement: Enzymetic method.;Insuline. Timepoint: prior to the study and 3 month after. Method of measurement: ElISA.;HOMA score. Timepoint: prior to the study and 3 month after. Method of measurement: Insulin (mU/L) * FSG(mmol/L) /22.5.;HbA1c. Timepoint: prior to the study and 3 month after. Method of measurement: HPLC chromatography.;Total Antioxidant Capacity. Timepoint: prior to the study and 3 month after. Method of measurement: spectrophotometry.;Malondialdehyde. Timepoint: prior to the study and 3 month after. Method of measurement: spectrophotometry.;Superoxide dismutase. Timepoint: prior to the study and 3 month after. Method of measurement: spectrophotometry.;Catalase. Timepoint: prior to the study and 3 month after. Method of measurement: spectrophotometry.;Nitric oxide. Timepoint: prior to the study and 3 month after. Method of measurement: spectrophotometry.;Protein carbonil. Timepoint: prior to the study and 3 month after. Method of measurement: spectrophotometry.	—

Measure

Time frame

Srume pentosidine. Timepoint: prior to the study and 3 month after. Method of measurement: ElISA.;Carboxymethyllysine. Timepoint: prior to the study and 3 month after. Method of measurement: ElISA.;SRAGE. Timepoint: prior to the study and 3 month after. Method of measurement: ElISA.;TG-Total cholestrol-LDL- HDL. Timepoint: prior to the study and 3 month after. Method of measurement: ElISA.;Fasting blood suger. Timepoint: prior to the study and 3 month after. Method of measurement: Enzymetic method.;Insuline. Timepoint: prior to the study and 3 month after. Method of measurement: ElISA.;HOMA score. Timepoint: prior to the study and 3 month after. Method of measurement: Insulin (mU/L) * FSG(mmol/L) /22.5.;HbA1c. Timepoint: prior to the study and 3 month after. Method of measurement: HPLC chromatography.;Total Antioxidant Capacity. Timepoint: prior to the study and 3 month after. Method of measurement: spectrophotometry.;Malondialdehyde. Timepoint: prior to the study and 3 month after. Method of measurement: spectrophotometry.;Superoxide dismutase. Timepoint: prior to the study and 3 month after. Method of measurement: spectrophotometry.;Catalase. Timepoint: prior to the study and 3 month after. Method of measurement: spectrophotometry.;Nitric oxide. Timepoint: prior to the study and 3 month after. Method of measurement: spectrophotometry.;Protein carbonil. Timepoint: prior to the study and 3 month after. Method of measurement: spectrophotometry.

—

Secondary

Measure	Time frame
Systolic diastolic blood pressure. Timepoint: prior to the study and 3 month after. Method of measurement: Digital manometer.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShiva Hoojeghani

Tabriz university of Medical science

Shiva.hoojeghani@gmail.com+98 41 3335 7581

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026